Disease · MONDO_0006052
Comparisons in its trials13
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 13 of 13
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| 4-Month Arm vs 6-Month Arm: Bacteriologic or Clinical Relapse at 30 Months After Onset of Initial Anti-tuberculosis (TB) Treatment - Intention-to-treat | 13 of 196 | 3 of 198 | 394 | NCT00130247 | Trial comparisons |
| 4-Month Arm vs 6-Month Arm: serious adverse events | 19 of 196 | 22 of 198 | 394 | NCT00130247 | Trial comparisons |
| 4-Month Arm vs 6-Month Arm: Bacteriologic or Clinical Relapse at 30 Months After Onset of Initial Anti-TB Treatment - Per-protocol | 13 of 185 | 3 of 185 | 370 | NCT00130247 | Trial comparisons |
| Drug Sensitive-TB 2HRZE/4HR vs Drug Sensitive-TB 4BPaMZ: Number of Participants With Culture Negative Status by 8 Weeks | 70 of 148 | 122 of 145 | 293 | NCT03338621 | Trial comparisons |
| Moxifloxacin vs Control: Proportion of Patients With Any Grade 3 or 4 Adverse Reactions in the Two Study Arms | 43 of 98 | 25 of 98 | 196 | NCT02114684 | Trial comparisons |
| Moxifloxacin vs Control: deaths from any cause | 6 of 98 | 4 of 98 | 196 | NCT02114684 | Trial comparisons |
| Moxifloxacin vs Control: Proportion of Patients With Unfavourable Outcomes or Tuberculosis Recurrence in the Moxifloxacin and Control Arm. | 13 of 98 | 6 of 98 | 196 | NCT02114684 | Trial comparisons |
| Moxifloxacin vs Control: serious adverse events | 27 of 98 | 12 of 98 | 196 | NCT02114684 | Trial comparisons |
| Experimental Arm vs Control Arm: Proportion of Patients With Grade 3 or 4 Adverse Reactions Attributable to Study Medications | 0 of 74 | 0 of 72 | 146 | NCT00082173 | Trial comparisons |
| Experimental Arm vs Control Arm: serious adverse events | 6 of 74 | 6 of 72 | 146 | NCT00082173 | Trial comparisons |
| Experimental Arm vs Control Arm: Proportion of Patients With Sterile Sputum Cultures | 59 of 64 | 45 of 61 | 125 | NCT00082173 | Trial comparisons |
| HPZM vs HRZE: serious adverse events | 0 of 62 | 0 of 59 | 121 | NCT00728507 | Trial comparisons |
| 4-Month Arm vs 6-Month Arm: Acquired Drug Resistance in Patients Who Relapsed | 0 of 13 | 0 of 3 | 16 | NCT00130247 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006052/comparisons